Navidea Biopharmaceuticals Obtains Positive European Medicines Evaluation Agency Guidance for Lymphoseek® (Tilmanocept); Company to Submit Marketing Authorization Application in Europe

Published: Feb 02, 2012

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it intends to file a Marketing Authorization Application (MAA) in the EU for Lymphoseek® (Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection) based on clinical data accumulated from completed pivotal studies and supporting clinical literature.

Back to news